Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Carcinoma, Hepatocellular 11Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 10Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 8Colorectal Neoplasms 8Rectal Neoplasms 5Advanced Solid Tumor 5Head and Neck Neoplasms 4Triple Negative Breast Neoplasms 3Esophageal Neoplasms 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Neoplasm, Residual 2Nasopharyngeal Carcinoma 2Lymphoma 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Advanced Solid Tumour 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of External Auditory Canal 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Simpson-Golabi-Behmel syndrome 1Sarcoma 1Renal Pelvic Carcinoma 1

Interventions

tislelizumab 1nedaplatin 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Immunotherapy Esophagus Cancer × tislelizumab × Clear all
NCT05515315 2024-02-07

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Fuzhou General Hospital

Phase 2 Recruiting
93 enrolled
Gastrointestinal

Immunotherapy Esophagus Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡